Antiphospholipid antibody profiling - Time for a new technical approach?

Autoimmunity Reviews

Volumn 11, Issue 11, 2012, Pages 821-826

  Roggenbuck, Dirk ^a,d   Egerer, Karl ^b   von Landenberg, Philipp ^c   Hiemann, Rico ^a   Feist, Eugen ^b   Burmester, Gerd Rüdiger ^b   Dörner, Thomas ^b  

^a Lausitz University of Applied Sciences   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Burgerspital Solothurn   (Switzerland)

^d GA GENERIC ASSAYS GMBH   (Germany)

Author keywords

Antiphospholipid antibody; Antiphospholipid syndrome; Beta2 glycoprotein I; Cardiolipin; Multi line immunodot assay; Phosphatidylinositol; Phosphatidylserine

Indexed keywords

FLUORIDE; PHOSPHOLIPID ANTIBODY; POLYVINYLIDENEDIFLUORIDE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYDROPHOBICITY; IMMUNOASSAY; IMMUNODOT ASSAY; LABORATORY DIAGNOSIS; MEMBRANE; NONHUMAN; REVIEW; SOLID;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; IMMUNOLOGIC TESTS;

EID: 84865381067     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.02.016     Document Type: Review

References (67)

1. Hughes G.R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983, 287:1088-1089.
2. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
3. Cervera R., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Kiss E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009, 68:1428-1432.
4. Gatto M., Iaccarino L., Canova M., Zen M., Nalotto L., Ramonda R., et al. Pregnancy and vasculitis: a systematic review of the literature. Autoimmun Rev 2011, [Dec 3, Electronic publication ahead of print].
5. Asherson R.A., Cervera R., DE Groot P.G., Erkan D., Boffa M.C., Piette J.C., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12:530-534.
6. Erkan D., Espinosa G., Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010, 10:74-79.
7. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
8. Pengo, V, Ruiz-Irastorza, G, Denas, G, Andreoli, L, Khamashta, M, Tincani, A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS', Autoimmun Rev 2011 [Oct 22, Electronic publication ahead of print].
9. Ceccarelli, F, Chighizola, C, Finazzi, G, Meroni, PL, Valesini G. Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons", Autoimmun Rev 2011 [Oct 22, Electronic publication ahead of print].
10. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
11. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
12. Devreese K., Hoylaerts M.F. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem 2010, 56:930-940.
13. Lackner K.J., Peetz D., von Landenberg P. Revision of the Sapporo criteria for the antiphospholipid syndrome- coming to grips with evidence and Thomas Bayes?. Thromb Haemost 2006, 95:917-919.
14. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9:A299-A304.
15. Scoble T., Wijetilleka S., Khamashta M.A. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011, 10:669-673.
16. Alessandri C., Conti F., Pendolino M., Mancini R., Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011, 10:609-616.
17. Prinz N., Hauser F., Lorenz M., Lackner K.J., Von L.P. Structural and functional characterization of a human IgG monoclonal antiphospholipid antibody. Immunobiology 2011, 216:145-151.
18. de Laat B., de Groot P.G. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011, 13:70-76.
19. Horstman L.L., Jy W., Bidot C.J., Ahn Y.S., Kelley R.E., Zivadinov R., et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation 2009, 6:3.
20. Egerer K., Roggenbuck D., Buttner T., Lehmann B., Kohn A., Von L.P., et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther 2011, 13:R118.
21. Petrovas C., Vlachoyiannopoulos P.G., Kordossis T., Moutsopoulos H.M. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999, 13:347-355.
22. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med 2004, 10:17-18.
23. Jahn S., Roggenbuck D., Settmacher U., Schwab J., Bohn J., Kiessig S.T., et al. The natural polyspecific autoantibody repertoire of man. Z Arztl Fortbild Qualitatssich (Jena) 1994, 88:479-484.
24. Quan C.P., Watanabe S., Pamonsinlapatham P., Bouvet J.P. Different dysregulations of the natural antibody repertoire in treated and untreated HIV-1 patients. J Autoimmun 2001, 17:81-87.
25. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
26. Steinerova A., Racek J., Stozicky F., Tatzber F., Lapin A. Autoantibodies against oxidized LDL in the first phase of life. Low density lipoproteins. Clin Chem Lab Med 1999, 37:913-917.
27. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990, 336:177-178.
28. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
29. Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990, 335:1544-1547.
30. Forastiero R.R., Martinuzzo M.E., Kordich L.C., Carreras L.O. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996, 75:717-720.
31. Mirarabshahi, P, Abdelatti, M, Krilis, S. Post-translational oxidative modification of beta2-glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome, Autoimmun Rev 2011 [Dec 31, Electronic publication ahead of print].
32. Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994, 7:441-455.
33. Mizutani H., Engelman R.W., Kinjoh K., Kurata Y., Ikehara S., Good R.A. Prevention and induction of occlusive coronary vascular disease in autoimmune (W/B)F1 mice by haploidentical bone marrow transplantation: possible role for anticardiolipin autoantibodies. Blood 1993, 82:3091-3097.
34. Hayakawa K., Asano M., Shinton S.A., Gui M., Allman D., Stewart C.L., et al. Positive selection of natural autoreactive B cells. Science 1999, 285:113-116.
35. Harris E.N., Gharavi A.E., Boey M.L., Patel B.M., Mackworth-Young C.G., Loizou S., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2:1211-1214.
36. Pierangeli S.S., Favaloro E.J., Lakos G., Meroni P.L., Tincani A., Wong R.C., et al. Standards and reference materials for the anticardiolipin and anti-beta(2)glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 2012, 413:358-360.
37. Lakos G., Favaloro E.J., Harris E.N., Meroni P.L., Tincani A., Wong R.C., et al. International consensus guidelines on anticardiolipin and anti-beta(2) glycoprotein I testing: A report from the APL task force at the 13(th) international congress on antiphospholipid antibodies. Arthritis Rheum 2012, 64:1-10.
38. Cervera, R, Conti, F, Doria, A, Iaccarino, L, Valesini, G. Does seronegative antiphospholipid syndrome really exist?, Autoimmun Rev 2011 [Oct 22, Electronic publication ahead of print].
39. Iaccarino L., Ghirardello A., Canova M., Zen M., Bettio S., Nalotto L., et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 2011, 10:553-558.
40. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005, 93:1147-1152.
41. von Landenberg P., Scholmerich J., von Kempis J., Lackner K.J. The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis. A retrospective study from a single center. Immunobiology 2003, 207:65-71.
42. Otomo K., Atsumi T., Amengual O., Fujieda Y., Kato M., Oku K., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012, 64:504-512.
43. Conrad K., Roggenbuck D., Reinhold D., Sack U. Autoantibody diagnostics in clinical practice. Autoimmun Rev 2011, 11:207-211.
44. Metzger J., Von L.P., Kehrel M., Buhl A., Lackner K.J., Luppa P.B. Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies. Clin Chem 2007, 53:1137-1143.
45. Grossmann K., Roggenbuck D., Schroder C., Conrad K., Schierack P., Sack U. Multiplex assessment of non-organ-specific autoantibodies with a novel microbead-based immunoassay. Cytometry A 2011, 79:118-125.
46. Schoenherr G., Roggenbuck D., Seifert M., Jahn S., Porstmann T. Technical problems arising from the use of the immunoblot for determination of the reactivity of natural antibodies with different lipopolysaccharides (LPS). J Immunol Methods 1996, 190:185-188.
47. Conrad K., Schneider H., Ziemssen T., Talaska T., Reinhold D., Humbel R.L., et al. A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies. Ann N Y Acad Sci 2007, 1109:256-264.
48. Seifert M., Schoenherr G., Roggenbuck D., Marx U., von B.R. Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria. Hybridoma 1996, 15:191-198.
49. Chabraoui F., Derrington E.A., Mallie-Didier F., Confavreux C., Quincy C., Caudie C. Dot-blot immunodetection of antibodies against GM1 and other gangliosides on PVDF-P membranes. J Immunol Methods 1993, 165:225-230.
50. Arvieux J., Roussel B., Jacob M.C., Colomb M.G. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods 1991, 143:223-229.
51. Matsuura E., Igarashi Y., Yasuda T., Triplett D.A., Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994, 179:457-462.
52. de Groot P.G., Derksen R.H., de Laat B. Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost 2008, 34:347-355.
53. Pierangeli S.S., Silva L.K., Harris E.N. A flow cytometric assay for the detection of antiphospholipid antibodies. Am Clin Lab 1999, 18:18-19.
54. Forastiero R.R., Martinuzzo M.E., Carreras L.O. Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot. Clin Exp Immunol 1999, 118:480-486.
55. Bevers E.M., Zwaal R.F., Willems G.M. The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin. Clin Immunol 2004, 112:150-160.
56. Chamorro, AJ, Marcos, M, Miron-Canelo, JA, Cervera, R, Espinosa, G. Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-analysis, Autoimmun Rev 2012 [Jan 8, Electronic publication ahead of print].
57. Conrad K., Roggenbuck D., Ittenson A., Reinhold D., Buettner T. Laass 2011, MW, A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency, Clin Chem Lab Med, [Oct 25, Electronic publication ahead of print].
58. Ruffatti A., Olivieri S., Tonello M., Bortolati M., Bison E., Salvan E., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008, 6:1693-1696.
59. Escalante A., Brey R.L., Mitchell B.D., Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995, 98:559-565.
60. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997, 28:1660-1665.
61. Danowski A., de Azevedo M.N., de Souza Papi J.A., Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009, 36:1195-1199.
62. Zoghlami-Rintelen C., Vormittag R., Sailer T., Lehr S., Quehenberger P., Rumpold H., et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005, 3:1160-1165.
63. Miesbach W. Neurologic symptoms as a feature of the antiphospholipid syndrome. Semin Thromb Hemost 2008, 34:286-289.
64. Nash M.J., Camilleri R.S., Kunka S., Mackie I.J., Machin S.J., Cohen H. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost 2004, 2:1077-1081.
65. Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214:683-691.
66. von Landenberg C., Lackner K.J., von Landenberg P., Lang B., Schmitz G. Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimmun 1999, 13:215-223.
67. Celli C.M., Gharavi A.E., Chaimovich H. Opposite beta2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity. Biochim Biophys Acta 1999, 1416:225-238.